235 related articles for article (PubMed ID: 20856791)
1. Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.
Samad N; Younes A
Onco Targets Ther; 2010 Sep; 3():167-78. PubMed ID: 20856791
[TBL] [Abstract][Full Text] [Related]
2. Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.
Galimberti S; Petrini M
Cancer Manag Res; 2010 Jun; 2():181-9. PubMed ID: 21188109
[TBL] [Abstract][Full Text] [Related]
3. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
Hess G; Smith SM; Berkenblit A; Coiffier B
Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
[TBL] [Abstract][Full Text] [Related]
4. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
5. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and management of temsirolimus in patients with relapsed or refractory mantle cell lymphoma.
Coiffier B
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):351-9. PubMed ID: 23763923
[TBL] [Abstract][Full Text] [Related]
7. Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
Kirschey S; Wagner S; Hess G
Clin Med Insights Oncol; 2012; 6():153-64. PubMed ID: 22550404
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
[TBL] [Abstract][Full Text] [Related]
9. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
Witzig TE; Geyer SM; Ghobrial I; Inwards DJ; Fonseca R; Kurtin P; Ansell SM; Luyun R; Flynn PJ; Morton RF; Dakhil SR; Gross H; Kaufmann SH
J Clin Oncol; 2005 Aug; 23(23):5347-56. PubMed ID: 15983389
[TBL] [Abstract][Full Text] [Related]
11. Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects.
Bouabdallah K; Ribrag V; Terriou L; Soria JC; Delarue R
Curr Opin Oncol; 2013 Mar; 25 Suppl 2():S1-12. PubMed ID: 23388840
[TBL] [Abstract][Full Text] [Related]
12. NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.
Balaji S; Ahmed M; Lorence E; Yan F; Nomie K; Wang M
J Hematol Oncol; 2018 Jun; 11(1):83. PubMed ID: 29907126
[TBL] [Abstract][Full Text] [Related]
13. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.
Coiffier B; Ribrag V
Leuk Lymphoma; 2009 Dec; 50(12):1916-30. PubMed ID: 19757306
[TBL] [Abstract][Full Text] [Related]
14. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B
J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539
[TBL] [Abstract][Full Text] [Related]
15. [Mantle Cell Lymphoma - Cutting edge Dia-gnostics and Treatment Approaches].
Klener P; Trněný M
Klin Onkol; 2015; 28 Suppl 3():3S80-6. PubMed ID: 26489506
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T
Tessoulin B; Bouabdallah K; Burroni B; Lamy T; Gressin R; Cartron G; Thieblemont C; Sarkozy C; Haioun C; Casasnovas O; Joubert C; Gyan E; Hermine O; Le Gouill S
Ann Hematol; 2020 Aug; 99(8):1771-1778. PubMed ID: 32601796
[TBL] [Abstract][Full Text] [Related]
17. Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis.
Hess G; Coiffier B; Crump M; Gisselbrecht C; Offner F; Romaguera J; Kang L; Moran PJ
Exp Hematol Oncol; 2015; 4():11. PubMed ID: 25938001
[TBL] [Abstract][Full Text] [Related]
18. Temsirolimus for the treatment of mantle cell lymphoma.
Hess G
Expert Rev Hematol; 2009 Dec; 2(6):631-40. PubMed ID: 21082954
[TBL] [Abstract][Full Text] [Related]
19. Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.
Wang L; Shi WY; Wu ZY; Varna M; Wang AH; Zhou L; Chen L; Shen ZX; Lu H; Zhao WL; Janin A
J Hematol Oncol; 2010 Sep; 3():30. PubMed ID: 20828385
[TBL] [Abstract][Full Text] [Related]
20. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
Avivi I; Goy A
Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]